APA

Lawitz E., Buti M., Vierling J. M., Almasio P. L., Bruno S., Ruane P. J., Hassanein T. I., Muellhaupt B., Pearlman B., Jancoriene L., Gao W., Huang H., Shepherd A., Tannenbaum B., Fernsler D., Li J. J., Grandhi A., Liu H., Su F., Wan S., Dutko F. J., Nguyen B. T., Wahl J., Robertson M. N., Barr E., Yeh W. W., Plank R. M., Butterton J. R. & Yoshida E. M. (20180723). Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. : The lancet. Gastroenterology & hepatology.

Chicago

Lawitz Eric, Buti Maria, Vierling John M, Almasio Piero L, Bruno Savino, Ruane Peter J, Hassanein Tarek I, Muellhaupt Beat, Pearlman Brian, Jancoriene Ligita, Gao Wei, Huang Hsueh-Cheng, Shepherd Aimee, Tannenbaum Brynne, Fernsler Doreen, Li Jerry J, Grandhi Anjana, Liu Hong, Su Feng-Hsiu, Wan Shuyan, Dutko Frank J, Nguyen Bach-Yen T, Wahl Janice, Robertson Michael N, Barr Eliav, Yeh Wendy W, Plank Rebeca M, Butterton Joan R and Yoshida Eric M. 20180723. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. : The lancet. Gastroenterology & hepatology.

Harvard

Lawitz E., Buti M., Vierling J. M., Almasio P. L., Bruno S., Ruane P. J., Hassanein T. I., Muellhaupt B., Pearlman B., Jancoriene L., Gao W., Huang H., Shepherd A., Tannenbaum B., Fernsler D., Li J. J., Grandhi A., Liu H., Su F., Wan S., Dutko F. J., Nguyen B. T., Wahl J., Robertson M. N., Barr E., Yeh W. W., Plank R. M., Butterton J. R. and Yoshida E. M. (20180723). Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. : The lancet. Gastroenterology & hepatology.

MLA

Lawitz Eric, Buti Maria, Vierling John M, Almasio Piero L, Bruno Savino, Ruane Peter J, Hassanein Tarek I, Muellhaupt Beat, Pearlman Brian, Jancoriene Ligita, Gao Wei, Huang Hsueh-Cheng, Shepherd Aimee, Tannenbaum Brynne, Fernsler Doreen, Li Jerry J, Grandhi Anjana, Liu Hong, Su Feng-Hsiu, Wan Shuyan, Dutko Frank J, Nguyen Bach-Yen T, Wahl Janice, Robertson Michael N, Barr Eliav, Yeh Wendy W, Plank Rebeca M, Butterton Joan R and Yoshida Eric M. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. : The lancet. Gastroenterology & hepatology. 20180723.